Clinical Pharmacology Study Group

1. AbbVie, Inc. $928,635 210 payments
2. Amgen Inc. $360,530 5 payments
3. Gilead Sciences, Inc. $69,816 20 payments
4. Regeneron Pharmaceuticals, Inc. $67,398 6 payments
5. Sun Pharmaceutical Industries Inc. $55,462 77 payments
6. GlaxoSmithKline, LLC. $21,292 10 payments
7. Pfizer Inc. $18,201 4 payments
8. Eli Lilly and Company $15,001 5 payments
9. E.R. Squibb & Sons, L.L.C. $13,548 4 payments
10. GRT US Holding, Inc. $140 2 payments

1. Interchangeability Study - ABP 654 $238,774 3 payments
2. M15-554 $152,681 11 payments
3. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) $143,969 38 payments
4. Interchangeability Study ABP 654 $121,756 2 payments
5. M15-998 $119,782 12 payments
6. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) $93,930 28 payments
7. M15-572 $66,989 12 payments
8. A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or intolerance to Biologic Therapy(ies) (KEEPsAKE 2) $61,852 15 payments
9. Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) $51,272 13 payments
10. A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $50,894 3 payments

1. Other $1,801 27 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.